Drugs / PX-12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00736372 | Jun 2008 → Aug 2009 | metastatic malignant neoplasm | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00417287 Comparator | Dec 2006 → Apr 2009 | malignant pancreatic neoplasm | Cascadian Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PX-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00417287 ↗ |
| Known as | 1-methylpropyl 2-imidazolyl disulfide | “PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a novel small molecule inhibitor of thioredoxin-1, a small protein over-expressed in many human cancers that is associated with...” NCT00736372 ↗ |
| Action | Inhibit | “inhibition of PX-12 target thioredoxin-1” NCT00417287 ↗1“Thioredoxin inhibitor” CHEMBL406050 ↗ |
| Modality | Small molecule | “PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a novel small molecule inhibitor” NCT00736372 ↗ |
| Route | Intravenous | “3 hour intravenous infusion” NCT00417287 ↗ |
| Target | TXN | “Thioredoxin inhibitor” CHEMBL406050 ↗ |